AR064937A1 - Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas, su preparacion y su aplicacion en terapeutica - Google Patents

Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas, su preparacion y su aplicacion en terapeutica

Info

Publication number
AR064937A1
AR064937A1 ARP080100206A ARP080100206A AR064937A1 AR 064937 A1 AR064937 A1 AR 064937A1 AR P080100206 A ARP080100206 A AR P080100206A AR P080100206 A ARP080100206 A AR P080100206A AR 064937 A1 AR064937 A1 AR 064937A1
Authority
AR
Argentina
Prior art keywords
cycloalkyl
aryl
alkylene
alkyl
group
Prior art date
Application number
ARP080100206A
Other languages
English (en)
Inventor
Laurent Dubois
Yannick Evanno
Andre Malanda
Christian Maloizel
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Publication of AR064937A1 publication Critical patent/AR064937A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Procedimiento de preparacion y aplicacion en terapéutica. Los compuestos presentan actividad antagonista in vivo e in vitro para los receptores de tipo TRPV1 o (VR1). Reivindicacion 1: Compuesto que responde a la formula general (1): en la que: X1, X2, X3, X4 representan, independientemente uno de otro, un átomo de hidrogeno o de halogeno o un grupo: alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-3, fluoroalquilo C1-6, alcoxilo C1-6, fluoroalcoxilo C1-6, ciano, C(O)NR1R2, nitro, NR1R2, tioalquilo C1-6, -S(O)-alquilo C1-6, -S(O)2-alquilo C1-6, SO2NR1R2, NR3COR4, NR3SO2R5 o arilo, estando el arilo eventualmente sustituido por uno o varios sustituyentes elegidos entre: un halogeno, un grupo alquilo C1-6, cicloalquilo C3- 7, cicloalquil C3-7-alquileno C1-3, fluoroalquilo C1-6, alcoxilo C1-6, fluoroalcoxilo C1-6, nitro o ciano; W representa un grupo bicíclico condensado de formula (2) unido al átomo de nitrogeno por las posiciones 1, 2, 3 o 4; A representa un heterociclo de 5 a 7 eslabones que comprende de uno a tres heteroátomos elegidos entre O, S o N; estando el o los átomos de carbono de A eventualmente sustituidos por uno o varios grupos elegidos entre: un átomo de hidrogeno o un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquilo C3-7-alquileno C1-3, fluoroalquilo C1-6, alcoxilo C1-6, cicloalcoxilo C3-7, cicloalquil C3-7-alquilen C1-3-oxi, arilo, aril-alquileno C1-6, oxo o tio; estando el o los átomos de nitrogeno de A eventualmente sustituidos por R6 cuando el nitrogeno es adyacente a un átomo de carbono sustituido por un grupo oxo o por R7 en los otros casos; Y representa un heteroarilo eventualmente sustituido por uno o varios grupos elegidos entre: un átomo de halogeno o un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-3, fluoroalquilo C1-6, hidroxilo, alcoxilo C1-6, fluoroalcoxilo C1-6, tiofluoroalquilo C1-6, ciano, C(O)NR1R2, nitro, NR1R2, tioalquilo C1-6, SH, -S(O)-alquilo C1-6, -S(O)2-alquilo C1-6, -S(O)-cicloalquilo C3-7, -S(O)2-cicloalquilo C3-7; SO2NR1R2, NR3COR4, NR3SO2R5, aril-alquileno C1-6 o arilo, estando el arilo y el aril-alquileno C1-6 eventualmente sustituidos por uno o varios sustituyentes elegidos entre: un halogeno, un grupo alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-3, fluoroalquilo C1-6, alcoxilo C1-6, fluoroalcoxilo C1-6, nitro o ciano; R1 y R2, representan, independientemente uno de otro, un átomo de hidrogeno o un grupo: alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-3, aril-alquileno C1-6 o arilo o R1 y R2 forman conjuntamente, con el átomo de nitrogeno que los lleva, un grupo: azetidinilo, pirrolidinilo, piperidinilo, azepinilo, morfolinilo, tiomorfolinilo, piperazinilo, homopiperazinilo, estando este grupo eventualmente sustituido por un grupo: alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-3, aril-alquileno C1-6 o arilo; R3 y R4 representan, independientemente uno de otro, un átomo de hidrogeno o un grupo: alquilo C1-6, aril-alquileno C1-6 o arilo; R5 representa un grupo alquilo C1-6, aril-alquileno C1-6 o arilo; R6 representa un átomo de hidrogeno o un grupo: alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-3, fluoroalquilo C1-6, aril-alquileno C1-6 o arilo; R7 representa un átomo de hidrogeno o un grupo: alquilo C1-6, cicloalquilo C3-7, cicloalquil C3-7-alquileno C1-3, fluoroalquilo C1-6, aril-alquileno C1-6, alquil C1-6-C(O)-, cicloalquil C3-7-alquilen C1-3-(CO)-, fluoroalquil C1-6-C(O)-, cicloalquil C3-7-C(O)-, aril-C(O)-, aril-alquilen C1-6-C(O)-, alquil C1-6-S(O)2-, fluoroalquil C1-6-S(O)2-, cicloalquil C3-7-S(O)2-, cicloalquil C3-7-alquilen C1-3-S(O)2-, aril-S(O)2- o aril-alquilen C1-6-S(O)2- o arilo, pudiendo estar el o los átomos de azufre del heterociclo A o del heteroarilo Y en forma oxidada; pudiendo estar el o los átomos de nitrogeno del heterociclo A o del heteroarilo Y en forma oxidada; en el estado de base o de sal de adicion de ácido, así como en el estado de hidrato o de solvato.
ARP080100206A 2007-01-19 2008-01-17 Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas, su preparacion y su aplicacion en terapeutica AR064937A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0700357A FR2911604B1 (fr) 2007-01-19 2007-01-19 Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
AR064937A1 true AR064937A1 (es) 2009-05-06

Family

ID=38283097

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100206A AR064937A1 (es) 2007-01-19 2008-01-17 Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas, su preparacion y su aplicacion en terapeutica

Country Status (11)

Country Link
US (1) US7868024B2 (es)
EP (1) EP2125787B1 (es)
JP (1) JP5264773B2 (es)
AR (1) AR064937A1 (es)
CL (1) CL2008000127A1 (es)
ES (1) ES2624795T3 (es)
FR (1) FR2911604B1 (es)
PE (1) PE20081689A1 (es)
TW (1) TW200900058A (es)
UY (1) UY30874A1 (es)
WO (1) WO2008107544A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
FR2888847B1 (fr) * 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
FR2926555B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives bicycliques de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926556B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
FR2926554B1 (fr) * 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
SG10201610416TA (en) 2012-06-13 2017-01-27 Incyte Corp Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
SI2986610T1 (en) 2013-04-19 2018-04-30 Incyte Holdings Corporation Bicyclic heterocycles as inhibitors of FGFR
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MX2020004108A (es) 2015-02-20 2022-01-03 Incyte Corp Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019213544A2 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
TW201946630A (zh) 2018-05-04 2019-12-16 美商英塞特公司 Fgfr抑制劑之鹽
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
IL291901A (en) 2019-10-14 2022-06-01 Incyte Corp Bicyclyl heterocycles as fgr suppressors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2024026290A1 (en) * 2022-07-25 2024-02-01 Cayman Chemical Company Incorporated NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1343782T1 (sl) 2000-12-21 2009-10-31 Smithkline Beecham Corp Pirimidinamini kot modulatorji angiogeneze
PL373484A1 (en) 2001-12-10 2005-09-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
TW200403223A (en) * 2002-02-15 2004-03-01 Glaxo Group Ltd Novel compounds
JP4909068B2 (ja) * 2003-02-14 2012-04-04 グラクソ グループ リミテッド カルボキサミド誘導体
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
FR2874015B1 (fr) * 2004-08-05 2006-09-15 Sanofi Synthelabo Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2888847B1 (fr) * 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
FR2897061B1 (fr) * 2006-02-03 2010-09-03 Sanofi Aventis Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.

Also Published As

Publication number Publication date
ES2624795T3 (es) 2017-07-17
UY30874A1 (es) 2008-09-02
FR2911604B1 (fr) 2009-04-17
TW200900058A (en) 2009-01-01
CL2008000127A1 (es) 2008-05-23
JP5264773B2 (ja) 2013-08-14
JP2010516662A (ja) 2010-05-20
EP2125787A1 (fr) 2009-12-02
EP2125787B1 (fr) 2017-03-01
FR2911604A1 (fr) 2008-07-25
US7868024B2 (en) 2011-01-11
PE20081689A1 (es) 2008-12-31
US20090306143A1 (en) 2009-12-10
WO2008107544A1 (fr) 2008-09-12

Similar Documents

Publication Publication Date Title
AR064937A1 (es) Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas, su preparacion y su aplicacion en terapeutica
AR054857A1 (es) Derivados de n- (heteroaril)-1- heteroarilquil-1 h - indol-2- carboxamidas, su preparacion y su aplicacion en terapeutica
AR061946A1 (es) Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas, su preparacion y composiciones farmaceuticas
AR070208A1 (es) Derivados de carboxamidas n- azabiciclicas su preparacion y su aplicacion en terapeutica
AR052450A1 (es) Derivados de n-(heteroaril)-1h- indol-2-carboxamidas , supreparacion y su aplicacion en terapeutica
AR062143A1 (es) Derivados de n-(amino- heteroaril)-1h-indol-2-carboxamidas y un procedimiento de preparacion
AR070207A1 (es) Derivados biciclicos de carboxamidas aza- biciclicas su preparacion y su aplicacion terapeutica
AR061642A1 (es) Derivados de ureas de tropano, su preparacion y su aplicacion en terapeu-tica, procesos de obtencion y composiciones farmaceuticas
ECSP077215A (es) Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas, su preparación y su aplicación en terapéutica
AR064524A1 (es) Derivados de n-(amino-(hetero)aril)-1h-pirrolopiridin-2-carboxamidas, su preparacion, intermediarios para su sintesis, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por los receptores de tipo trpv1.
CO6251251A2 (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
AR057668A1 (es) Derivados de n-(arilalquil)-1h-pirrolopiridin-2-carboxamidas, su preparacion, composiciones farmaceuticas y su aplicacion en terapeutica
CY1117862T1 (el) Ετεροκυκλικες ενωσεις βενζοδιοξολιου ή βενζοδιοξεπινης ως αναστολεις φωσφοδιεστερασης
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
AR066954A1 (es) Derivados de 7- alquinil-1,8- naftiridonas , su preparacion y su aplicacion en terapeutica
CO5721001A2 (es) Derivados sustituidos de morfolina y tiomorfolina
CO6351734A2 (es) Compuestos de amida utiles en terapia
CR10643A (es) DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
CO5560573A2 (es) Derivados activos de amino-ftalazinona como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los contienen
CY1113687T1 (el) Παραγωγα αμινο νικοτινικου και ισο-νικοτινικου οξεος σαν παραγοντες καταστολης της dhodh
AR072753A1 (es) Derivados de oxazina como inhibidores de 11 beta - hidroxiesteroiode deshidrogenasa 1
EA201070896A1 (ru) ЗАМЕЩЕННЫЕ АРИЛАМИДДИАЗЕПИНОПИРИМИДОНОВЫЕ ПРОИЗВОДНЫЕ ДЛЯ ЛЕЧЕНИЯ НЕЙРОДЕГЕНЕРАТИВНЫХ ЗАБОЛЕВАНИЙ, ВЫЗВАННЫХ АНОМАЛЬНОЙ АКТИВНОСТЬЮ GSK3β
AR070206A1 (es) Derivados de carboxamidas azabiciclicas su preparacion y su aplicacion en terapeutica
AR055744A1 (es) Derivados de acido pirimidincarboxilico, su uso para preparar medicamentos y preparacion de dicjhos compuestos
PE20080136A1 (es) Arilsulfonamidas sustituidas como agentes antivirales

Legal Events

Date Code Title Description
FA Abandonment or withdrawal